Medtronic and Recor Medical each announced separate Medicare reimbursement approvals for their respective renal denervation ...

payment for the Medtronic Symplicity Spyral ™ renal denervation (RDN) catheter, used in the Symplicity ™ blood pressure procedure, under the Medicare Hospital Outpatient Prospective Payment ...

payment for the Medtronic Symplicity Spyral™ renal denervation (RDN) catheter, used in the Symplicity™ blood pressure procedure, under the Medicare Hospital Outpatient Prospective Payment System. TPT ...

Approved by the U.S. Food and Drug Administration (FDA) in November 2023, the Medtronic Symplicity Spyral ... inserts a single thin tube (known as a catheter) into the artery leading to the ...

The lawsuit was brought against Medtronic by New York resident Charles Riegel following the rupture of a Medtronic catheter in his coronary artery during heart surgery. He suffered severe injuries as ...

About a year ago, renal denervation procedures won a huge victory after finally being greenlit by FDA. Now two of the frontrunners in the space have received reimbursement.

Medtronic has announced that the US Food and Drug Administration (FDA) has approved the Affera mapping and ablation system featuring the Sphere-9 Catheter. This innovative, all-in-one system ...

Medtronic plc, a global leader in healthcare technology, announced the United States Food and Drug Administration (FDA) has approval of the Affera Mapping and Ablation System with Sphere-9 catheter, ...

Medtronic has obtained the Centers for Medicare & Medicaid Services (CMS) transitional pass-through (TPT) payment for the Symplicity Spyral renal denervation (RDN) catheter. Set to be effective from 1 ...

The Affera Mapping and Ablation System and Sphere-9 catheter also received CE Mark in March 2023 and was approved in Australia in September 2024. In October 2024, Medtronic announced the start of ...

For more information on Affera and the Sphere-9 catheter, visit Medtronic.com. Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's ...

This approval is expected to help in treatment of persistent AFib and for RF ablation of CTI dependent atrial flutter.